Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients. The Company was founded and is led by an experienced team of biotechnology founders and executives.

For questions regarding investment opportunities, email: investors@printbio.com

Recent Updates

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

egalli | News, Press Releases | No Comments

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan • Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company • $19…

PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting

egalli | Press Releases | No Comments

PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…

PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025

egalli | Press Releases | No Comments

DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in surgical repair. By giving surgeons programmable control over mesh mechanics,…

View All